Who makes Placebo of Indapamide (P2)?

Placebo of Indapamide (P2) is developed by Hospices Civils de Lyon.

What development phase is Placebo of Indapamide (P2) in?

Placebo of Indapamide (P2) is FDA-approved (marketed).

Last reviewed 2026-04-22 · How we verify

Placebo of Indapamide (P2)

Hospices Civils de Lyon · FDA-approved active Small molecule

This is a placebo control with no active pharmacological mechanism.

At a glance

Generic name	Placebo of Indapamide (P2)
Sponsor	Hospices Civils de Lyon
Modality	Small molecule
Phase	FDA-approved

Mechanism of action

As a placebo of indapamide, this formulation contains no active drug and produces no direct pharmacological effect. It is used as a control comparator in clinical trials to assess the efficacy and safety of the active indapamide formulation by isolating the true drug effect from placebo response.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results